

## Disclosures

### Personal Commercial (63)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	
Agios Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	
AHA	<i>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</i>	Significant (>= \$5,000)	
Alexion Pharma	Research/Research Grants	Significant (>= \$5,000)	
Alnylam	Research/Research Grants	Significant (>= \$5,000)	
Amgen Inc.	Research/Research Grants	Significant (>= \$5,000)	Prevention
Angionetics	Research/Research Grants	Significant (>= \$5,000)	
Anthos Therapeutics	<i>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</i>	Significant (>= \$5,000)	
ARCA	Research/Research Grants ‡ ASPEN COVID 19	Significant (>= \$5,000)	Other
ARCA biopharma, Inc.	Research/Research Grants ‡ ASPEN COVID 19	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Array	Research/Research Grants	Significant (>= \$5,000)	
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ PEGASUS-TIMI 54, REAL-TIMI 63B, ALETHEIA real world dataset	Significant (>= \$5,000)	Prevention
Atentiv	Research/Research Grants	Significant (>= \$5,000)	
Audentes	Research/Research Grants	Significant (>= \$5,000)	
Bayer	Research/Research Grants ‡ VOYAGER PAD	Significant (>= \$5,000)	Prevention
Better Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Prevention
Brigham and Women's Hospital	Research/Research Grants	Significant (>= \$5,000)	
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	
Cambrian Biopharma	<i>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</i>	Significant (>= \$5,000)	
Cardiol Therapeutics	Research/Research Grants	Significant (>= \$5,000)	
CellResearch	Research/Research Grants	Significant (>= \$5,000)	
Cleerly	<i>Other - Grant support to CPC</i>	Significant (>= \$5,000)	Prevention
Cook Regentec	Research/Research Grants	Significant (>= \$5,000)	
CSL Behring	Research/Research Grants	Significant (>= \$5,000)	
Eidos Therapeutics	Research/Research Grants	Significant (>= \$5,000)	
EP Trading Company	Research/Research Grants	Significant (>= \$5,000)	
EPG Communications	<i>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</i>	Modest (< \$5,000)	
Epizon Pharma	<i>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</i>	Significant (>= \$5,000)	
Esperion	Research/Research Grants	Significant (>= \$5,000)	
EverlyWell	Research/Research Grants	Significant (>= \$5,000)	
Faraday Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Fortress Biotech	Research/Research Grants	Significant (>= \$5,000)	
Heartflow	Research/Research Grants	Significant (>= \$5,000)	
Insmed	Research/Research Grants	Significant (>= \$5,000)	
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ PREVENT HD, VOYAGER PAD	Significant (>= \$5,000)	Prevention
Kowa Research	Research/Research Grants	Significant (>= \$5,000)	
Lexicon	Research/Research Grants	Significant (>= \$5,000)	
Medtronic	Stock	Modest (< \$5,000)	Other
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Moderna	Research/Research Grants	Significant (>= \$5,000)	
NIH	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Novartis Corporation	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
NovoNordisk	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Pfizer Inc	Stock	Modest (< \$5,000)	Other
Pfizer Inc	Research/Research Grants	Significant (>= \$5,000)	
PhaseBio	Research/Research Grants	Significant (>= \$5,000)	
PPD Development	Research/Research Grants	Significant (>= \$5,000)	
Prothena Biosciences	Research/Research Grants	Significant (>= \$5,000)	
Regeneron	Research/Research Grants	Significant (>= \$5,000)	
Regio Biosciences	Research/Research Grants	Significant (>= \$5,000)	
Sanifit	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	
Silence Therapeutics	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
St. Luke's Hospital of Kansas City	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Stealth BioTherapeutics	Research/Research Grants	Significant (>= \$5,000)	
Thrombosis Research Institute	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
University of Colorado	Research/Research Grants	Significant (>= \$5,000)	
University of Pittsburgh	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
VarmX	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Vertex Pharmaceuticals	Stock	Significant (>= \$5,000)	Other
Worldwide Clinical Trials	Research/Research Grants	Significant (>= \$5,000)	
Wraser	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Yale Cardiovascular Research Group	Research/Research Grants	Significant (>= \$5,000)	

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2013	aortic dissection	Defendant	Missed aortic dissection	Significant (>= \$5,000)

*† Commercial Funding Source | ‡ Trial Name*

## Agreement

**Certified Education Attestation** | Signed on 1/9/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 1/9/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 1/9/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 1/9/2024

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.